RBM 007

Drug Profile

RBM 007

Alternative Names: RBM007

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ribomic
  • Class Peptide aptamers
  • Mechanism of Action Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Achondroplasia; Age-related macular degeneration; Bone disorders; Cancer pain
  • Research Fibrosis

Most Recent Events

  • 21 Jul 2016 Early research in Fibrosis in Japan (unspecified route)
  • 21 Jul 2016 Preclinical trials in Achondroplasia in Japan (unspecified route)
  • 21 Jul 2016 Preclinical trials in Age-related macular degeneration in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top